Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083379 | 0.83 | ALOX5AP (0.34) | ARFEN1ALOX5AP | |
| SCHEMBL23191208 | 0.78 | ALOX5AP (0.32) | ARFEN1ALOX5AP | |
| SCHEMBL15322243 | 0.76 | — | — | |
| SCHEMBL16798341 | 0.74 | KCNH2 (0.35) | ARKCNH2HDAC6 | |
| SCHEMBL14394660 | 0.74 | PIM1 (0.40) | ARKCNH2JAK2 | |
| SCHEMBL2186892 | 0.74 | EPHX2 (0.38) | ARKCNH2HDAC6IDO1TDO2 | |
| SCHEMBL18010537 | 0.72 | — | — | |
| SCHEMBL15033960 | 0.72 | — | — | |
| SCHEMBL15885884 | 0.72 | — | — | |
| SCHEMBL612055 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515591-B | Method for preparing tyrosine receptor kinase inhibitor | 派拉米德生物科学公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. | 2023-08-03 | — | — | US | disclosed |
| CN-115515591-A | Process for preparing tyrosine receptor kinase inhibitors | 派拉米德生物科学公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021211882-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | PYRAMID BIOSCIENCES, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242536-A1 | METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS | LTK, FRK, LCK | AR 862/4885FEN1 1117/4885ABL1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.